Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)

Dupilumab reduces oral corticosteroid use in patients with corticosteroid-dependent severe asthma: An analysis of the phase 3, open-label extension TRAVERSE trial

(2022) Lawrence D. Sher et al.   CHEST

Biologic Therapies for Severe Asthma

(2022) Guy G. Brusselle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of combining biologics in severe asthma: asthma‐related and unrelated combinations

(2022) Marek Lommatzsch et al.   ALLERGY

Disease-modifying anti-asthmatic drugs

(2022) Marek Lommatzsch et al.   LANCET

Overall response to anti-IL5/anti-IL5Rα treatment in severe asthma does not depend on initial bronchodilator responsiveness

(2022) Carlo Mümmler et al.   Journal of Allergy and Clinical Immunology-In Practice

Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany

(2022) Karl-Christian Bergmann et al.   Journal of Asthma and Allergy

Response to monoclonal antibodies in asthma: definitions, potential reasons for failure and therapeutic options for suboptimal response

(2022) L Pérez de Llano et al.   JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY

German Regional Variation of Acute and High Oral Corticosteroid Use for Asthma

(2021) Cassandra Nan et al.   JOURNAL OF ASTHMA

Small Airway Dysfunction Links Asthma Severity with Physical Activity and Symptom Control

(2021) Mustafa Abdo et al.   Journal of Allergy and Clinical Immunology-In Practice

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study

(2021) Andrew Menzies-Gow et al.   Lancet Respiratory Medicine

Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma

(2021) Ian D. Pavord et al.   Journal of Allergy and Clinical Immunology-In Practice

Prediction of response to biological treatment with monoclonal antibodies in severe asthma

(2020) J.A. Kroes et al.   BIOCHEMICAL PHARMACOLOGY

EAACI Biologicals Guidelines—Recommendations for severe asthma

(2020) Ioana Agache et al.   ALLERGY

Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma

(2020) Joanne E. Kavanagh et al.   CHEST

Switching between biologics in severe asthma patients. When the first choice is not proven to be the best

(2020) Andriana I. Papaioannou et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Oral corticosteroid prescription for asthma by general practitioners: A three-year analysis in Germany

(2020) Marek Lommatzsch et al.   RESPIRATORY MEDICINE

An expert consensus framework for asthma remission as a treatment goal

(2019) Andrew Menzies-Gow et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

(2018) Klaus F. Rabe et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response

(2018) Nora Drick et al.   BMC Pulmonary Medicine

Baseline Patient Factor Impact on the Clinical Efficacy of Benralizumab for Severe Asthma

(2018) Eugene R. Bleecker et al.   EUROPEAN RESPIRATORY JOURNAL

Role of Biologics in Asthma

(2018) Mary Clare McGregor et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Severe eosinophilic asthma: a roadmap to consensus

(2017) Roland Buhl et al.   EUROPEAN RESPIRATORY JOURNAL

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

(2017) Parameswaran Nair et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The minimally important difference of the Asthma Control Test

(2009) Michael Schatz et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY